# InvestorNewsBreaks – TransCode Therapeutics, Inc. (NASDAQ: RNAZ) Advances RNA Cancer Therapy as 15 Patients Dosed in Phase 1a Trial

TransCode Therapeutics (NASDAQ: RNAZ) announced that the third patient in Cohort 4 of its Phase 1a trial for RNA-based cancer therapeutic TTX-MC138 has been dosed, with 15 patients now treated across four dose levels. The Safety Review Committee approved expanded enrollment and noted no significant toxicities or disease progression to date. Ten patients remain on study, with the longest treated showing stable disease after seven cycles. Early PK/PD data confirm target engagement and support advancing to the Phase 1b dose expansion stage.

 To view the full press release, visit https://ibn.fm/aoTBb

 About TransCode Therapeutics

 TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

 NOTE TO INVESTORS: The latest news and updates relating to MUX are available in the company’s newsroom at https://ibn.fm/RNAZ

 About InvestorWire

 InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

 For more information, please visit https://www.InvestorWire.com

 Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

 InvestorWireAustin, Texaswww.InvestorWire.com512.354.7000 OfficeEditor@InvestorWire.com

 InvestorWire is powered by IBN 

---

[Original/Source Press Release](https://rss.investorbrandnetwork.com/iw/investornewsbreaks-transcode-therapeutics-inc-nasdaq-rnaz-advances-rna-cancer-therapy-as-15-patients-dosed-in-phase-1a-trial/)
                    

[Newsramp.com TLDR](https://newsramp.com/curated-news/transcode-therapeutics-advances-rna-based-cancer-therapeutic-in-phase-1a-trial/8dcde9dab40f6be124107f65581102d4) 

 



[Reddit Post](https://www.reddit.com/r/Business_NewsRamp/comments/1khrojc/transcode_therapeutics_advances_rnabased_cancer/) 



![Blockchain Registration](https://cdn.newsramp.app/ibn/qrcode/255/8/cornCOkY.webp)